TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07445971: A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.

Sponsor: ModeX Therapeutics, An OPKO Health Company · Phase: PHASE1 · Area: INFECTIOUS_VACCINE · Target Enrollment: 80 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$6,397,440

Rescue Site Savings

+$4,218,312

Unlock Full NCT07445971 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07445971 Rescue Dossier →